去势抵抗性前列腺癌的治疗进展*

去势抵抗性前列腺癌是一种致死性疾病，进展快，常伴随着转移，预后极差，死亡率接近100% ，患者中位生存时间少于20个月，是前列腺癌治疗的热点和难题，其发生发展机制尚不明确。近些年来涌现出许多治疗去势抵抗性前列腺癌的新方法，包括新型雄激素受体拮抗剂、免疫治疗、紫杉烷类化疗药物、抗血管生成药物、放射性核素、骨靶向药物以及各疗法联合应用等，改善了患者的生存期。本文就去势抵抗性前列腺癌的治疗进展进行综述。

Treatment progress on castration-resistant prostate cancer

Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100%mortality, of which the median survival time is less than 20 months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antago-nists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone-targeting drugs. These therapies can im-prove the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this ar-ticle.